Buscar
27/10/2023
Frontline therapy in Chronic Lymphocytic Leukemia
Arguello-Tomas, M, Albiol, N, Moreno, C. Frontline therapy in Chronic Lymphocytic Leukemia. ACTA HAEMATOLOGICA. 2023; 147(1)DOI:10.1159/000534730. PMID:37899041. IF:1.700(Q3/8D).
21/10/2023
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Socié G., Barba P., Barlev A., Sanz J., García-Cadenas I., Chevallier P., Fagioli F., Guzman-Becerra N., Kumar D., Ljungman P., Pigneux A., Sadetsky N., Yáñez San Segundo L., Shadman M., Storek J., Thirumalai D., Xing B., Mohty M.. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy. BONE MARROW TRANSPLANTATION. 2023; 59(1)DOI:10.1038/s41409-023-02127-9. PMID:37865719. IF:4.500(Q1/2D).
01/10/2023
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Piñana, JL, Heras, I, Aiello, TF, García-Cadenas, I, Vazquez, L, Lopez-Jimenez, J, Chorao, P, Aroca, C, García-Vidal, C, Arroyo, I, Soler-Espejo, E, López-Corral, L, Avendaño-Pita, A, Arrufat, A, Garcia-Gutierrez, V, Arellano, E, Hernández-Medina, L, González-Santillana, C, Morell, J, Hernández-Rivas, JA, Rodriguez-Galvez, P, Mico-Cerdá, M, Guerreiro, M, Campos, D, Navarro, D, Cedillo, A, Martino, R, Solano, C. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients. Viruses-Basel. 2023; 15(10)DOI:10.3390/v15102066. PMID:37896843. IF:3.800(Q2/5D).
01/09/2023
mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect
Albiol, N, Lynton-Pons, E, Aso, O, Moga, E, Vidal, S, Gomez-Perez, L, Santiago, JA, Triquell, M, Roch, N, Lazaro, E, Gonzalez, I, Lopez-Contreras, J, Esquirol, A, Sierra, J, Martino, R, Garcia-Cadenas, I. mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect. LEUKEMIA RESEARCH. 2023; 132DOI:10.1016/j.leukres.2023.107347. PMID:37356281. IF:2.100(Q3/6D).
16/08/2023
Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances
Pinana, JL, Perez, A, Chorao, P, Guerreiro, M, Garcia-Cadenas, I, Solano, C, Martino, R, Navarro, D. Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances. Transplant Infectious Disease. 2023; DOI:10.1111/tid.14117. PMID:37585370. IF:2.600(Q2/5D).
15/08/2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Woyach, JA, Ghia, P, Byrd, JC, Ahn, IE, Moreno, C, O'Brien, SM, Jones, D, Cheung, LWK, Chong, ELZB, Kwei, K, Dean, JP, James, DF, Wiestner, A. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. CLINICAL CANCER RESEARCH. 2023; 29(16)DOI:10.1158/1078-0432.CCR-22-3887. PMID:37314786. IF:10.400(Q1/1D).
02/08/2023
Development of an in-house bone marrow collection kit: The Catalan bone marrow transplantation group experience
Fernandez-Sojo J., Valdivia E., Esquirol A., Portos, JM, Rovira M., Suarez M., Diaz-de-Heredia C., Uria, ML, Ortí G., Ferra C., Mussetti A., Paviglianiti A., Marsal J., Badell I., Lozano M., Gomez D., Azqueta C., Martorell L., Rubio N., Garcia-Buendia A., Villa J., Carreras E., Querol S.. Development of an in-house bone marrow collection kit: The Catalan bone marrow transplantation group experience. VOX SANGUINIS. 2023; 118(9)DOI:10.1111/vox.13499. PMID:37533171. IF:1.800(Q3/7D).
20/07/2023
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
Munir, T, Moreno, C, Owen, C, Follows, G, Benjamini, O, Janssens, A, Levin, MD, Osterborg, A, Robak, T, Simkovic, M, Stevens, D, Voloshin, S, Vorobyev, V, Yagci, M, Ysebaert, L, Qi, KQ, Qi, QY, Parisi, L, Srinivasan, S, Schuier, N, Baeten, K, Howes, A, Caces, DB, Niemann, CU, Kater, AP. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(21)DOI:10.1200/JCO.22.02283. PMID:37279408. IF:42.100(Q1/1D).